| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d12fcf94a35348198bf31558dcff2cf6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-82 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-82
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 |
| filingDate |
1992-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_558aca2ebe32ca1f2151519f4e45ea8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_927aa65ec459e7fcd67d48ab30fe4e15 |
| publicationDate |
1992-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9222303-A1 |
| titleOfInvention |
Selective inhibition of leukemic cell proliferation by bcr-abl antisense oligonucleotides |
| abstract |
Leukemias characterized by the presence of the Philadelphia chromosome and the expression of the hybrid bcr-abl gene are treated with antisense oligonucleotides complementary to a target sequence of the bcr-abl mRNA transcript including the breakpoint junction. Individual chronic myelogoneous leukemia patients or Philadelphia chromosome-positive acute lymphocytic leukemia patients are treated by first sequencing the individual's bcr-abl breakpoint junction, and then administering antisense oligonucleotides complementary thereto. The oligonucleotides are designed to hybridize specifically to the bcr-abl breakpoint junction without substantial cross hybridization to untranslocated c-abl sequences. Treatment may comprise in vivo administration of antisense oligonucleotides, or ex vivo treatment such as bone marrow purging. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5583034-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2726004-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018291366-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7176302-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9627663-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9507923-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9612803-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9718305-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9718305-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9746672-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9746672-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8044032-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010184933-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9824928-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6005095-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5618709-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5635385-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11371038-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9627663-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9503788-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9324653-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0458829-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9824928-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7754872-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5989849-A |
| priorityDate |
1991-06-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |